Can adding radiation at the right time boost immunotherapy for aggressive lung cancer?

NCT ID NCT06768307

First seen Aug 17, 2026 ยท Last updated Aug 17, 2026

Summary

This study is exploring whether giving radiotherapy at the same time as immunotherapy and chemotherapy, versus giving it after, works better as a first treatment for extensive-stage small cell lung cancer. The trial will enroll about 60 adults with this advanced cancer. Participants will receive the immunotherapy drug adebrelimab alongside standard chemotherapy, with radiation either during the fourth cycle or later. The goal is to see which timing helps delay cancer progression and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
adebrelimab (an immunotherapy drug) combined with chemotherapy and radiotherapy
What this could lead to
If successful, this could establish a more effective first-line treatment for extensive-stage small cell lung cancer, potentially improving how long patients live without the disease progressing.
What could go wrong
This is an early-phase exploratory study with a small number of participants, so results may not be definitive. Combining immunotherapy with radiation can increase side effects, and the benefit over current standard care is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking University Cancer Hospital and Institute

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.